U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C47H51NO14
Molecular Weight 853.9079
Optical Activity UNSPECIFIED
Defined Stereocenters 11 / 11
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PACLITAXEL

SMILES

CC1=C2[C@]([H])(C(=O)[C@]3(C)[C@]([H])(C[C@]4([H])[C@@](CO4)([C@@]3([H])[C@@]([H])([C@](C[C@]1([H])OC(=O)[C@@]([H])([C@]([H])(c5ccccc5)N=C(c6ccccc6)O)O)(C2(C)C)O)OC(=O)c7ccccc7)OC(=O)C)O)OC(=O)C

InChI

InChIKey=RCINICONZNJXQF-MZXODVADSA-N
InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1

HIDE SMILES / InChI

Molecular Formula C47H51NO14
Molecular Weight 853.9079
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 10 / 11
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf and https://www.ncbi.nlm.nih.gov/pubmed/18068131

Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a US National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. Later it was discovered that endophytic fungi in the bark synthesize paclitaxel. When it was developed commercially by Bristol-Myers Squibb (BMS), the generic name was changed to paclitaxel and the BMS compound is sold under the trademark Taxol. In this formulation, paclitaxel is dissolved in Kolliphor EL and ethanol, as a delivery agent. Taxol is marketed for the treatment of Breast cancer; Gastric cancer; Kaposi's sarcoma; Non-small cell lung cancer; Ovarian cancer. A newer formulation, in which paclitaxel is bound to albumin, is sold under the trademark Abraxane. Paclitaxel is a taxoid antineoplastic agent indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast cancer. Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis. Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer. Paclitaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, paclitaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, paclitaxel binds to the β subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of paclitaxel locks these building blocks in place. The resulting microtubule/paclitaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that paclitaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function.

CNS Activity

Curator's Comment:: No or negligible penetration of paclitaxel over an intact blood– brain barrier

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: HeLa cell growth
7.08 µM [IC50]
Target ID: SKOV3 breast cancer cell growth
38.7 nM [IC50]
23.0 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TAXOL

Approved Use

TAXOL is indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary.

Launch Date

8.9907842E11
Primary
TAXOL

Approved Use

TAXOL is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.

Launch Date

8.9907842E11
Primary
TAXOL

Approved Use

TAXOL, in combination with cisplatin, is indicated for the first-line treatment of nonsmall cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy.

Launch Date

8.9907842E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6.92 μM
250 mg/m² steady-state, intravenous
dose: 250 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
PACLITAXEL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.5 μM
175 mg/m² steady-state, intravenous
dose: 175 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
PACLITAXEL plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
27.07 μM × h
250 mg/m² steady-state, intravenous
dose: 250 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
PACLITAXEL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
14.8 h
175 mg/m² steady-state, intravenous
dose: 175 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
PACLITAXEL plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
6.5%
PACLITAXEL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
135 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 135 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 135 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, adult
Other AEs: Anaphylaxis, Dyspnea...
Other AEs:
Anaphylaxis (2%)
Dyspnea (severe, 2%)
Hypotension (severe, 2%)
Generalized urticaria (severe, 2%)
Angioedema (severe, 2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Anaphylaxis 2%
135 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 135 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 135 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, adult
Angioedema severe, 2%
135 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 135 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 135 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, adult
Dyspnea severe, 2%
135 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 135 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 135 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, adult
Generalized urticaria severe, 2%
135 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 135 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 135 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, adult
Hypotension severe, 2%
135 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 135 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 135 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, adult
PubMed

PubMed

TitleDatePubMed
Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study.
1999 Dec
Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells.
1999 Jul
Acute encephalopathy: a new toxicity associated with high-dose paclitaxel.
1999 Mar
Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells.
1999 Mar 19
Phase II of doxorubicin/taxol in metastatic breast cancer. Argentine Multicenter Taxol Group.
1999 May
Microtubules, but not actin filaments, drive daughter cell budding and cell division in Toxoplasma gondii.
2000 Apr
Schedule dependency of paclitaxel-induced neuropathy in mice: a morphological study.
2000 Aug
Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies.
2000 Aug
Phase II clinical trials of cisplatin-then-paclitaxel and paclitaxel-then-cisplatin in patients with previously untreated advanced epithelial ovarian cancer.
2000 Dec
Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma.
2000 Dec
Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
2000 Dec 15
Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein.
2000 Jan
Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol.
2000 Jan 28
Biochemical mechanism of cross-resistance to paclitaxel in a mitomycin c-resistant human bladder cancer cell line.
2000 Mar 31
Second-line chemotherapy with paclitaxel, cisplatin and gemcitabine in pre-treated sensitive cisplatin-based patients with advanced non-small cell lung cancer.
2000 May-Jun
Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy.
2000 Sep
Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species.
2000 Sep 1
A paclitaxel-containing chemotherapy does not cause central nervous adverse effects: a prospective study in patients with ovarian cancer.
2000 Sep-Oct
Doxorubicin and paclitaxel in the treatment of advanced breast cancer: efficacy and cardiac considerations.
2001
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
2001
In vivo metabolism of epothilone B in tumor-bearing nude mice: identification of three new epothilone B metabolites by capillary high-pressure liquid chromatography/mass spectrometry/tandem mass spectrometry.
2001
Cell cycle-related changes in regulatory volume decrease and volume-sensitive chloride conductance in mouse fibroblasts.
2001 Apr
Connexin 43 (cx43) enhances chemotherapy-induced apoptosis in human glioblastoma cells.
2001 Apr 1
Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300.
2001 Apr 13
Regional drug delivery with radiation for the treatment of Ewing's sarcoma. In vitro development of a taxol release system.
2001 Apr 2
Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial.
2001 Feb
Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
2001 Feb
Gemcitabine plus cisplatin in breast cancer.
2001 Feb
Phytochemistry and medicinal plants.
2001 Feb
Membrane macrophage colony-stimulating factor on MADB106 breast cancer cells does not activate cytotoxic macrophages but immunizes rats against breast cancer.
2001 Feb
Changes in glycosylation during Drosophila development. The influence of ecdysone on hemomucin isoforms.
2001 Feb
Study of multi-drug resistant mechanisms in a taxol-resistant hepatocellular carcinoma QGY-TR 50 cell line.
2001 Feb 9
Receptor-mediated cell modulator delivery to hepatocyte using nanoparticles coated with carbohydrate-carrying polymers.
2001 Jan
Stimulation of taxol production and excretion in Taxus spp cell cultures by rare earth chemical lanthanum.
2001 Jan 23
The role of actin filaments and microtubules in hepatocyte spheroid self-assembly.
2001 Mar
Dynamic events are differently mediated by microfilaments, microtubules, and mitogen-activated protein kinase during porcine oocyte maturation and fertilization in vitro.
2001 Mar
Effects of stathmin inhibition on the mitotic spindle.
2001 Mar
Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie study.
2001 Mar 1
Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3.
2001 Mar 1
Paclitaxel restores radiation-induced apoptosis in a bcl-2-expressing, radiation-resistant lymphoma cell line.
2001 Mar 15
Regulation of ROMK1 channels by protein-tyrosine kinase and -tyrosine phosphatase.
2001 Mar 9
Insulin-like growth factor-I receptor antagonism results in increased cytotoxicity of breast cancer cells to doxorubicin and taxol.
2001 Mar-Apr
Inhibition of telomerase activity as a measure of tumor cell killing by cisplatin in squamous cell carcinoma cell line.
2001 Mar-Apr
P-glycoprotein efflux pump expression and activity in Calu-3 cells.
2001 May
Regulation of stress-responsive mitogen-activated protein (MAP) kinase pathways by TAO2.
2001 May 11
Regulation of BRCA1 and BRCA2 transcript in response to cisplatin, adriamycin, taxol and ionising radiation is correlated to p53 functional status in ovarian cancer cell lines.
2001 May-Jun
Patents

Sample Use Guides

For previously untreated patients with carcinoma of the ovary, one of the following recommended regimens may be given every 3 weeks. a.TAXOL (PACLITAXEL) administered intravenously over 3 hours at a dose of 175 mg/m2 followed by cisplatin at a dose of 75 mg/m2; or b.TAXOL (PACLITAXEL) administered intravenously over 24 hours at a dose of 135 mg/m2 followed by cisplatin at a dose of 75 mg/m2 2) In patients previously treated with chemotherapy for carcinoma of the ovary, the recommended regimen is TAXOL (PACLITAXEL) 135 mg/m2 or 175 mg/m2 administered intravenously over 3 hours every 3 weeks.
Route of Administration: Intravenous
Paclitaxel inhibited tubulin polymerization in the presence of MAPs in vitro with an IC50 value of 38.19 ± 3.33 uM in living cancer cells (Hela cells and human osteosarcoma U2OS cells).
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:05:55 UTC 2021
Edited
by admin
on Fri Jun 25 21:05:55 UTC 2021
Record UNII
P88XT4IS4D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PACLITAXEL
EMA EPAR   EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
ONCOGEL
Common Name English
PACLITAXEL [MART.]
Common Name English
EBETAXEL
Common Name English
PAXENE
Brand Name English
NSC-125973
Code English
INTAXEL
Common Name English
TAXOL
Brand Name English
PACLITAXEL [USAN]
Common Name English
MITOTAX
Common Name English
ABI-007 COMPONENT PACLITAXEL
Code English
PACLITAXEL [USP-RS]
Common Name English
BMS-181339-01
Code English
NAB-PACLITAXEL COMPONENT PACLITAXEL
Common Name English
ONXAL
Common Name English
GENETAXYL
Common Name English
MBT-0206
Code English
NK-105
Code English
PACLITAXEL [ORANGE BOOK]
Common Name English
BENZENEPROPANOIC ACID, .BETA.-(BENZOYLAMINO)-.ALPHA.-HYDROXY-, (2AR,4S,4AS,6R,9S,11S,12S,12AR,12BS)-6,12B-BIS(ACETYLOXY)-12-(BENZOYLOXY)-2A,3,4,4A,5,6,9,10,11,12,12A,12B-DODECAHYDRO-4,11-DIHYDROXY-4A,8,13,13-TETRAMETHYL-5-OXO-7,11-METHANO-1H-CYCLODECA(3,
Systematic Name English
DHP-107
Code English
PACLITAXEL [USP]
Common Name English
CAPXOL
Common Name English
PACLITAXEL [MI]
Common Name English
PACLITAXEL [VANDF]
Common Name English
GENEXOL
Brand Name English
PACLITAXEL [GREEN BOOK]
Common Name English
EMPAC
Common Name English
PLAXICEL
Common Name English
GENEXOL-PM
Common Name English
ABI 007 COMPONENT PACLITAXEL
Common Name English
TAXUS
Common Name English
PACLITAXEL [EP MONOGRAPH]
Common Name English
PACLIEX
Common Name English
ENDOTAG 1
Common Name English
(-)-PACLITAXEL
Common Name English
PACLITAXEL [USP MONOGRAPH]
Common Name English
LIPOSOME-ENTRAPPED PACLITAXEL EASY-TO-USE
Common Name English
TAXOL A
Common Name English
PACLITAXEL (TAXUS CANADENSIS)
Common Name English
ABRAXANE COMPONENT PACLITAXEL
Brand Name English
PACLITAXEL [EMA EPAR]
Common Name English
PACLITAXEL [INN]
Common Name English
GENAXOL
Common Name English
PACLITAXEL [JAN]
Common Name English
TAXALBIN
Common Name English
YEWTAXAN
Brand Name English
PACLITAXEL [WHO-DD]
Common Name English
CYCLOPAX
Common Name English
PACLITAXOL
Common Name English
LEP-ETU
Common Name English
TAXUS STENT
Common Name English
ZISU
Brand Name English
TOCOSOL PACLITAXEL
Common Name English
QW-8184
Code English
PACLITAXEL [HSDB]
Common Name English
ONXOL
Brand Name English
TAXUS LIBERTE
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 270208
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
FDA ORPHAN DRUG 50190
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
NDF-RT N0000175085
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
LIVERTOX 730
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
FDA ORPHAN DRUG 394813
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
NCI_THESAURUS C67437
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
EU-Orphan Drug EU/3/06/422
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
FDA ORPHAN DRUG 454014
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
WHO-VATC QL01CD01
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
FDA ORPHAN DRUG 594217
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
FDA ORPHAN DRUG 469915
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
FDA ORPHAN DRUG 103497
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
FDA ORPHAN DRUG 186404
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
FDA ORPHAN DRUG 482015
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
NDF-RT N0000175592
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
FDA ORPHAN DRUG 278309
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
FDA ORPHAN DRUG 384912
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
FDA ORPHAN DRUG 104797
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
FDA ORPHAN DRUG 454114
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
EMA ASSESSMENT REPORTS PAXENE (WITHDRAWN: OVARIAN NEOPLASMS)
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
CFR 21 CFR 516.1684
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
FDA ORPHAN DRUG 290709
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
FDA ORPHAN DRUG 252907
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
NCI_THESAURUS C1490
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
WHO-ATC L01CD01
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
EMA ASSESSMENT REPORTS ABRAXANE (AUTHORIZED: PANCREATIC NEOPLASMS)
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
FDA ORPHAN DRUG 291009
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
EMA ASSESSMENT REPORTS PAXENE (WITHDRAWN: CARCINOMA, NON-SMALL-CELL LUNG)
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
FDA ORPHAN DRUG 141701
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
FDA ORPHAN DRUG 280409
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
Code System Code Type Description
CAS
33069-62-4
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
MESH
D017239
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
USP_CATALOG
1491332
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY USP-RS
HSDB
6839
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
ChEMBL
CHEMBL428647
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
EPA CompTox
33069-62-4
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
DRUG BANK
DB01229
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
IUPHAR
2770
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
FDA UNII
P88XT4IS4D
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
INN
7052
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
WIKIPEDIA
PACLITAXEL
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
RXCUI
56946
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
EVMPD
SUB09583MIG
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
NCI_THESAURUS
C1411
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
PUBCHEM
36314
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
MERCK INDEX
M8351
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY Merck Index
LACTMED
Paclitaxel
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
MESH
C495179
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
DRUG CENTRAL
2044
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
PRIMARY
RXCUI
486610
Created by admin on Fri Jun 25 21:05:55 UTC 2021 , Edited by admin on Fri Jun 25 21:05:55 UTC 2021
ALTERNATIVE
Related Record Type Details
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> INDUCER
Paclitaxel activates pregnane X receptor (PXR)
METABOLIC ENZYME -> INDUCER
METABOLIC ENZYME -> INDUCER
Paclitaxel activates pregnane X receptor (PXR)
TRANSPORTER -> SUBSTRATE
BINDER->LIGAND
BINDING
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
METABOLITE -> PARENT
In vitro studies with human liver microsomes and tissue slices showed that paclitaxel was metabolized primarily to 6α-hydroxypaclitaxel by CYP2C8; and to two minor metabolites, 3'-p-hydroxypaclitaxel and 6α, 3'-p-dihydroxypaclitaxel, by CYP3A4.
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC